Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Current Assets (2016 - 2026)

Myriad Genetics has reported Current Assets over the past 16 years, most recently at $332.6 million for Q4 2025.

  • Quarterly Current Assets rose 11.61% to $332.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $332.6 million through Dec 2025, up 11.61% year-over-year, with the annual reading at $332.6 million for FY2025, 11.61% up from the prior year.
  • Current Assets was $332.6 million for Q4 2025 at Myriad Genetics, down from $344.8 million in the prior quarter.
  • Over five years, Current Assets peaked at $538.9 million in Q2 2021 and troughed at $261.6 million in Q1 2023.
  • The 5-year median for Current Assets is $305.8 million (2023), against an average of $341.5 million.
  • Year-over-year, Current Assets soared 62.47% in 2021 and then crashed 43.36% in 2022.
  • A 5-year view of Current Assets shows it stood at $484.8 million in 2021, then crashed by 43.36% to $274.6 million in 2022, then grew by 14.2% to $313.6 million in 2023, then decreased by 4.97% to $298.0 million in 2024, then rose by 11.61% to $332.6 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Current Assets are $332.6 million (Q4 2025), $344.8 million (Q3 2025), and $284.3 million (Q2 2025).